| NCT06727552 | A Study of Barzolvolimab in Patients With Atopic Dermatitis | RECRUITING | PHASE2 | 2025-01-07 | 2027-05 | 2026-10 |
| NCT06650761 | A Phase I Study of CDX-622 | RECRUITING | PHASE1 | 2024-11-01 | 2026-04 | 2026-04 |
| NCT06455202 | A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU) | RECRUITING | PHASE3 | 2024-07-19 | 2027-04 | 2026-10 |
| NCT06445023 | A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria | RECRUITING | PHASE3 | 2024-07-11 | 2027-04 | 2026-10 |
| NCT06366750 | A Study of Barzolvolimab in Patients With Prurigo Nodularis | RECRUITING | PHASE2 | 2024-04-12 | 2026-06 | 2026-01 |
| NCT05774184 | A Study of CDX-0159 in Patients With Eosinophilic Esophagitis | ACTIVE_NOT_RECRUITING | PHASE2 | 2023-06-01 | 2025-12 | 2025-06-04 |
| NCT05788484 | A Study of CDX-585 in Patients With Advanced Malignancies | COMPLETED | PHASE1 | 2023-05-11 | 2025-05-21 | 2025-05-21 |
| NCT05405660 | A Study of CDX-0159 in Patients With Chronic Inducible Urticaria | ACTIVE_NOT_RECRUITING | PHASE2 | 2022-06-28 | 2025-09 | 2024-06-12 |
| NCT05368285 | A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria | COMPLETED | PHASE2 | 2022-05-19 | 2024-12-20 | 2023-09-28 |
| NCT04944862 | A Study of CDX-0159 in Patients With Prurigo Nodularis | COMPLETED | PHASE1 | 2021-11-08 | 2023-07-31 | 2023-07-31 |
| NCT05031624 | A Phase 1 Study of Subcutaneous CDX-0159 in Healthy Subjects | COMPLETED | PHASE1 | 2021-08-30 | 2022-01-14 | 2022-01-14 |
| NCT04548869 | A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria | COMPLETED | PHASE1 | 2020-11-24 | 2023-05-12 | 2022-12-16 |
| NCT04538794 | A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria | COMPLETED | PHASE1 | 2020-09-24 | 2023-01-17 | 2023-01-17 |
| NCT04440943 | A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies | COMPLETED | PHASE1 | 2020-08-04 | 2023-04-06 | 2023-04-06 |
| NCT04146129 | A Phase 1 Study of CDX-0159 | COMPLETED | PHASE1 | 2019-10-29 | 2020-06-26 | 2020-04-06 |
| NCT03254927 | A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma | TERMINATED | PHASE2 | 2018-03-27 | 2020-12-16 | 2020-09-16 |
| NCT03329950 | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | COMPLETED | PHASE1 | 2017-12-01 | 2022-09-13 | 2022-09-13 |
| NCT02837991 | A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma | TERMINATED | PHASE1 | 2016-06 | 2018-11-16 | 2018-11-16 |
| NCT02642016 | A Study to Evaluate the Safety and Pharmacokinetics of CDX-0158 in Adult Patients With Advanced Solid Tumors | COMPLETED | PHASE1 | 2015-12 | 2019-06-04 | 2018-01-30 |
| NCT02543645 | A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer | TERMINATED | PHASE1 | 2015-10 | 2017-05-22 | 2017-04 |
| NCT02473731 | A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients | COMPLETED | PHASE1 | 2015-10 | 2016-10-10 | 2016-09-22 |
| NCT02456701 | Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379 | COMPLETED | PHASE1 | 2015-06 | 2016-10-13 | 2016-10-13 |
| NCT02386111 | A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma | TERMINATED | PHASE1 | 2015-05 | 2017-11-03 | 2017-08 |
| NCT02413827 | A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma | TERMINATED | PHASE1, PHASE2 | 2015-04 | 2016-11-09 | 2016-11-02 |
| NCT02335918 | A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors | COMPLETED | PHASE1, PHASE2 | 2015-01 | 2018-12-12 | 2018-12-12 |
| NCT02302339 | A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma | TERMINATED | PHASE2 | 2014-11 | 2018-10-03 | 2018-06-14 |
| NCT02200380 | A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs | TERMINATED | PHASE2 | 2014-07 | 2016-04-13 | 2016-03 |
| NCT02014909 | A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors | COMPLETED | PHASE1 | 2014-01 | 2017-06-05 | 2017-05-25 |
| NCT01997333 | Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer | COMPLETED | PHASE2 | 2013-11 | 2018-08-07 | 2017-11-30 |
| NCT01791686 | Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease | TERMINATED | PHASE1 | 2013-01 | 2014-03 | 2014-03 |
| NCT01498328 | A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma | COMPLETED | PHASE2 | 2011-12 | 2016-05-17 | 2015-04 |
| NCT01480479 | Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma | COMPLETED | PHASE3 | 2011-11 | 2016-11 | 2016-11 |
| NCT01460134 | A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers | COMPLETED | PHASE1 | 2011-10 | 2017-10-16 | 2015-12 |
| NCT01465139 | A Study to Evaluate CDX-301 (rhuFlt3L) in Healthy Volunteers | COMPLETED | PHASE1 | 2011-10 | 2013-01 | 2012-11 |
| NCT01156753 | A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer | COMPLETED | PHASE2 | 2010-07 | 2012-11 | 2012-10 |
| NCT01094496 | A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study) | TERMINATED | PHASE2 | 2010-04 | 2011-07 | 2011-07 |
| NCT00948961 | A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1 | COMPLETED | PHASE1, PHASE2 | 2009-09 | 2014-02 | 2012-06 |
| NCT00704158 | Study of CR011-vcMMAE to Treat Locally Advanced or Metastatic Breast Cancer | COMPLETED | PHASE1, PHASE2 | 2008-06 | 2011-06 | 2010-11 |
| NCT00458601 | Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme | COMPLETED | PHASE2 | 2007-08 | 2016-05 | 2010-11 |
| NCT00412828 | A Phase I/II Study of CR011-vcMMAE in Subjects With Unresectable Stage III or Stage IV Melanoma | COMPLETED | PHASE1, PHASE2 | 2006-06 | 2011-05 | 2010-12 |
| NCT00323518 | A Phase II Controlled Trial of Velafermin for Prevention of Oral Mucositis | COMPLETED | PHASE2 | 2006-05 | 2008-08 | 2008-08 |
| NCT00648102 | Phase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder or Ovarian Cancer | COMPLETED | PHASE1 | 2006-01 | 2009-12 | 2009-05 |
| NCT00104065 | Safety and Efficacy of CG53135-05 in the Prevention of Oral Mucositis in Patients Receiving Bone Marrow Transplant | COMPLETED | PHASE2 | 2005-01 | 2005-12 | 2005-12 |
| NCT00709462 | A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX 1307-01) | COMPLETED | PHASE1 | 2004-03 | 2010-06 | 2010-05 |